Identification of FDA approved drugs with anti-tumor activity in rhabdomyosarcoma.
|
Massachusetts General Hospital / David Langenau |
Young Investigator Grants |
2009 |
Massachusetts |
Investigating the Role of Circadian Rhythm in the Progression of Acute Myeloid Leukemia |
Boston Children’s Hospital / Samantha Morris, PhD |
Young Investigator Grants |
2013 |
Massachusetts |
The Role of ARID1A in Neuroblastoma Pathogenesis |
Dana-Farber Cancer Institute / Hui Shi, PhD |
Young Investigator Grants |
2016 |
Massachusetts |
Identification of Novel Treatment Targets by Exploring the Interaction of Rhabdomyosarcoma-Associated Oncogenes with Cellular Context in a Mouse Model of Rhabdomyosarcoma |
Dana-Farber Cancer Institute / Simone Hettmer |
Young Investigator Grants |
2010 |
Massachusetts |
Treatment of high-risk pediatric brain tumors with a CD133-targeted adenovirus in combination with temozolomide
|
University of Texas M.D. Anderson Cancer Center / Marta Alonso, PhD |
Young Investigator Grants |
2008 |
Texas |
Exploiting WT1 Genomic Alterations for Target Identification and MRD Monitoring in Pediatric AML |
Fred Hutchinson Cancer Research Center / Phoenix Ho |
Young Investigator Grants |
2012 |
Washington |
MYC-driven Core Regulatory Circuits in Neuroblastoma |
Dana-Farber Cancer Institute / Mark Zimmerman, PhD |
Young Investigator Grants |
2018 |
Massachusetts |
Elucidating the Mechanism of ERK Mediated Pathogenesis of LCH |
Baylor College of Medicine / Rikhia Chakraborty, PhD |
Young Investigator Grants |
2015 |
Texas |
Genetic Regulators of ER Stress-induced Apoptosis in Pediatric Malignancies
|
Dana-Farber Cancer Institute / Ujwal Pyati |
Young Investigator Grants |
2009 |
Massachusetts |
Pre-clinical Evaluation of LSD1 Inhibitors for the Treatment of Pediatric Ewing sarcoma: Defining the Biomarkers of Sensitivity and Mechanisms of Resistance |
Research Institute at Nationwide Children's Hospital / Kathleen Pishas, PhD |
Young Investigator Grants |
2016 |
Ohio |